Nexium Capsules Clinical Experience Investigation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01434485

Enrollment

3691

Registered

2011-09-15

Start date

2011-09-30

Completion date

2014-03-31

Last updated

2014-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,Non-erosive Reflux Disease, Zollinger-Ellison Syndrome

Keywords

gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome, Nexium

Brief summary

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, or Zollinger-Ellison syndrome

Detailed description

Nexium capsules Clinical Experience Investigation

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

- Patients treated with Nexium for the first time due to gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome.

Exclusion criteria

- None

Design outcomes

Primary

Measure	Time frame
Number of Adverse Drug Reactions	Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks

Countries

Japan

Outcome results